SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as the community rallies around its position as a Bitcoin-native meme coin within the burgeoning Rune ecosystem. Discussions highlight the strong community, fair distribution, and the potential for $DOG to bridge Bitcoin culture with broader markets through its association with $CBLO. The community emphasizes holding through market volatility.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as traders discuss its potential as a privacy-focused alternative to Bitcoin, drawing comparisons to early BTC gains. Community members are pointing to recent investments from figures like the Winklevoss twins, as well as speculation around institutional adoption and regulatory environments favoring privacy coins. Some traders believe ZEC is inversely correlated to Bitcoin and are closely watching technical patterns for potential breakouts.

Memecoin on Injective taken over by the community.

Nonja

$NONJA is gaining traction as a meme coin on the Injective ($INJ) network, with community members highlighting its strong performance relative to $INJ and its robust, active community.  Discussion revolves around its potential for high returns, especially with the upcoming Injective EVM mainnet and potential ETFs, and the unique qualities of its NFT collections.  The community emphasizes $NONJA's strong fundamentals, burned liquidity, and status as a leading meme coin on the $INJ ecosystem.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as the community discusses potential catalysts including a Wells Fargo upgrade, the possibility of Trump-era tariffs being overturned by the Supreme Court, and a potential boost from a collaboration with SKIMS. Some traders are pointing to technical indicators suggesting a potential breakout, while others express concerns about the company's performance and valuation. Speculation around an upcoming earnings report is also contributing to the heightened interest.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending amid discussions about its strategic shift towards AI and robotics, with the unveiling of the 'Iron' humanoid robot driving significant investor interest. The community is actively discussing the potential for XPEV to become a leader in physical AI, expanding beyond its current EV focus, with some comparing it favorably to Tesla. Bullish sentiment is also supported by strong delivery numbers and expansion into new global markets.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia (JMIA) is trending amid discussions about its Q3 earnings, long-term financial targets presented at its investor day, and a recent fund filing revealing a significant stake. Community members are focused on the company's potential for growth in the African market, its path to profitability, and potential short squeeze opportunities. Bullish sentiment appears to be building around JMIA's position as an uncorrelated asset and its long-term prospects in a growing market.

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cidara Therapeutics is trending due to positive sentiment around a potential acquisition by Merck for $9.2B, which sent the stock soaring. The community is discussing the impact of the deal on options, what happens to shares post-acquisition, and whether a bidding war might further increase the acquisition price. Some investors are also looking at similar companies that may be acquisition targets.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending as investors discuss its strong cash position, low share float, and Phase 3 trials targeting a significant patient population. The community is highlighting the potential for a squeeze, drawing comparisons to other stocks with similar ownership structures and catalysts. Some are noting potential institutional interest.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

$BRK.B is trending amid discussions around Warren Buffett's succession and Berkshire Hathaway's massive cash position, leading to speculation about upcoming strategic moves. The community is weighing the impact of Buffett's planned year-end departure and Greg Abel's potential focus on AI and energy sectors. Recent filings revealing new positions, like a stake in Google, and reduced positions in other holdings such as Apple, drive debate on Berkshire's evolving investment strategy.

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Cardinal Health, Inc.

Cardinal Health ($CAH) is trending due to recent analyst upgrades and a positive investor day highlighting growth strategies. Community discussions emphasize the company's potential for margin improvement and long-term value, while others point to an overbought RSI suggesting a possible short-term pullback. The stock is seen as an ole reliable pick in the healthcare distribution sector, with revenue over 200B.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuron (IMRN) CEO Steven Lydeamore stated in a letter to shareholders on Thursday that the company does not anticipate any material impact from the recently announced U.S. tariffs on pharmaceutical products.Nasdaq-listed shares of Immuron rallied 8% on Thursday morning following the news. The CEO <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160195/37134/en/Immuron-Letter-to-Shareholders-Projects-Update.html">stated</a> that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs.The Australia-based company also said that it is on track to exceed FY24 first-quarter (Q1) sales. The company is slated to report its Q1 FY25 sales in mid-October.Immuron has three therapeutic products under development, including IMM-124E, also known as Travelan, for traveler’s diarrhea. The company stated that it continues to expect trial results for this candidate in October 2025.“It is hoped that this trial will enable Travelan to be recommended in traveler’s diarrhea guidelines, thereby increasing its market potential,” the company said.As for IMM-529, which is under development for Clostridioides difficile infection, Immuron stated that it is progressing with an application to the U.S. Food and Drug Administration to initiate clinical development by mid-October. According to Immuron, the IMM-529 market in the U.S. is expected to reach peak revenues of approximately $400 million.The company has also advanced the launch of ProIBS, a medical product for treating symptoms related to Irritable Bowel Syndrome, to the fourth quarter from its previous estimate of Q1 2026. Immuron now anticipates a limited launch in Q4, with a full launch in Q1 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMRN">IMRN stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:574/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_12_28_03_PM_png_c36282e1fb.webp" alt="IMRN's Sentiment Meter and Message Volume as of 12:28 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="574" height="58"><figcaption>IMRN's Sentiment Meter and Message Volume as of 12:28 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the company’s updates.<stembedurl>https://stocktwits.com/Timtheshark/message/630768842</stembedurl>IMRN stock is up 22% this year but down approximately 24% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reports-7-percent-rise-in-q3-deliveries/chCrXlDR3Ow">Tesla’s Q3 Deliveries Hit Quarterly Record, Rise 7% To Exceed Analyst Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 

Equity

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 


Immuron Limited CEO to Present at Biotech Event

Immuron Limited (AU:IMC) has released an update. Immuron Limited, an Australian biopharmaceutical company, will feature CEO Steven Lydeamore presen...

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 07/03/2024

Gagnants
Le titre Ainos (NASDAQ:AIMD) a grimp jeudi de 101,78% 2,26 dollars lors de la session after-market.
Le titre Immuron (NASDAQ:IMRN) a grimp de 36,26% 6,20 dollars.
L'action Talis...

Immuron Announces Positive Results Support Travelan  progress to Phase 3 Clinical Trials in the US

Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy...

Immuron Presentation Australian Biologics Festival 2024

MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...

Immuron achieves record Travelan  sales

Highlights: Travelan sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan YTD Jan 2024 sales $2.1 millionUSA Travelan YTD Jan 2024 sales $0.6...

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...

Immuron achieves record half yearly Travelan  sales

Highlights: Record half yearly Travelan sales of $2,334,969Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales51% higher than pre-pandemic period H1, FY20 sales...

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group’s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

Immuron Limited - ADR

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

IMRN
IMMURON Ltd/S ADR

Feed

News

Sentiment

Fundamentals

Info

Latest IMRN News

IMRNIMMURON Ltd/S ADR